Avandamet and Cholesterol
During clinical studies on Avandamet and cholesterol, the diabetes medicine was shown to increase HDL cholesterol and significantly decrease LDL cholesterol, total cholesterol, and triglycerides. Since people with diabetes are at an increased risk for heart disease, it is especially important for them to maintain good cholesterol levels.
Avandamet® (rosiglitazone and metformin) is a prescription medication that has been licensed to treat type 2 diabetes. The drug is a combination of two different diabetes medications: rosiglitazone maleate (Avandia®) and metformin hydrochloride (Fortamet®, Glucophage®, Glucophage XR®, Glumetza®, or Riomet®). Although Avandamet has many beneficial effects on blood sugar, it may also have useful effects on cholesterol as well.
In September 2010, the U.S. Food and Drug Administration (FDA) announced that it was severely restricting the use of Avandamet, due to the risk of "cardiovascular events" such as heart attacks and strokes. Only individuals who could not control their diabetes on other medications (or those who were already taking the medication and doing well) would be able to take Avandamet.
However, in November 2013, the FDA announced that a careful analysis of the research suggests that there is not, in fact, any increased risk, compared to treatment with standard diabetes medications and that the use of this medication will no longer be restricted.
In studies, Avandamet lowered LDL cholesterol ("bad" cholesterol) by 0.2 percent and lowered total cholesterol by 2.2 percent on average. Avandamet lowered triglycerides by 18.7 percent. Also, Avandamet increased HDL cholesterol ("good" cholesterol) by 5.8 percent on average.